126 related articles for article (PubMed ID: 38113749)
1. Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib.
Chen J; Fang C; Chang C; Wang K; Jin H; Xu T; Hu J; Wu W; Shen E; Zhang K
Colloids Surf B Biointerfaces; 2024 Feb; 234():113710. PubMed ID: 38113749
[TBL] [Abstract][Full Text] [Related]
2. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
4. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
7. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
9. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer.
Seto K; Shimizu J; Masago K; Araki M; Katayama R; Sagae Y; Fujita S; Horio Y; Sasaki E; Kuroda H; Okubo K; Okuno Y; Hida T
Cancer Genet; 2022 Aug; 266-267():1-6. PubMed ID: 35598548
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
12. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S; Lin X; Sun S; Li S; Zhou C
Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
[TBL] [Abstract][Full Text] [Related]
13. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
[TBL] [Abstract][Full Text] [Related]
14. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
[No Abstract] [Full Text] [Related]
15. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
Dotsu Y; Fukuda M; Honda N; Gyotoku H; Kohno Y; Suyama T; Umeyama Y; Taniguchi H; Takemoto S; Yamaguchi H; Miyazaki T; Sakamoto N; Obase Y; Ikeda H; Ashizawa K; Mukae H
Thorac Cancer; 2021 Jan; 12(2):272-276. PubMed ID: 33215864
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
18. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
[No Abstract] [Full Text] [Related]
19. Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF
Kashizaki F; Tanaka A; Hattori S; Sugimoto S
Eur J Cancer; 2021 Jan; 143():31-32. PubMed ID: 33278771
[No Abstract] [Full Text] [Related]
20. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
